MARKET

BIOC

BIOC

Biocept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.89
+0.36
+5.51%
Opening 13:07 02/24 EST
OPEN
6.65
PREV CLOSE
6.53
HIGH
6.99
LOW
6.47
VOLUME
212.04K
TURNOVER
--
52 WEEK HIGH
13.00
52 WEEK LOW
2.110
MARKET CAP
92.30M
P/E (TTM)
-1.7399
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Biocept Inks Research Pact With Protean BioDiagnostics For Target Selector Kit Advantages In Lung Cancer
Benzinga · 1d ago
Liquid Biopsy Market Research Revealing the Growth Rate and Business Opportunities to 2027
Feb 23, 2021 (Heraldkeepers) -- Market Research Engine has published a new report titled as "Liquid Biopsy Market Size By Application (Non-Cancer...
Heraldkeepers · 1d ago
Biocept and Protean Biodiagnostics to tie up in lung cancer research deal
Biocept (BIOC) will collaborate with Protean BioDiagnostics to research the ability of Biocept’s Target Selector molecular assay to determine EGFR status in non-small cell lung cancer ((NSCLC)) patients.Biocept’s molecular assays
Seekingalpha · 1d ago
BRIEF-Biocept And Protean BioDiagnostics Establish Research Collaboration To Demonstrate Advantages Of Biocept’s Target Selector Assay Kit For Non-Small Cell Lung Cancer Patients
reuters.com · 1d ago
Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocepts Target Selector Assay Kit for Non-Small Cell Lung Cancer Patients
Biocept and Protean BioDiagnostics Collaborate to Demonstrate Advantages of Biocept’s Target Selector Assay for Non-Small Cell Lung Cancer Patients.
Business Wire · 1d ago
Circulating Tumor Cell Diagnostics Market Research Development, Top Companies, Trends And Growth 2018 To 2028
Feb 23, 2021 (Heraldkeepers) -- The report covers a detailed competitive outlook including the market share and company profiles of the key participants...
Heraldkeepers · 1d ago
Global Circulating Tumor Cell Diagnostics Market 2021 Research Report by Trends, Growth Drivers, Size, Share, Opportunities, Challenges, Risks and Influences Factors Analysis & Forecast to 2027
Feb 22, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The global “Circulating Tumor Cell...
The Express Wire · 1d ago
Liver Cancer Screening Market | 2021 Size, Share Estimation, Growth Projection, COVID-19 Impact On Business, Trends, Healthcare Sector, Regional Analysis, Competitive Landscape With Global Industry Forecast To 2026
Feb 22, 2021 (The Expresswire) -- Liver Cancer Screening Market | 2021 Healthcare Sector Analysis By Covid-19 Impact, Size, Share Estimation, Growth...
The Express Wire · 2d ago
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BIOC. Analyze the recent business situations of Biocept through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BIOC stock price target is 20.00 with a high estimate of 20.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 45
Institutional Holdings: 1.29M
% Owned: 9.66%
Shares Outstanding: 13.40M
TypeInstitutionsShares
Increased
4
62.43K
New
12
193.80K
Decreased
5
84.53K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.88%
Healthcare Equipment & Supplies
+0.82%
Key Executives
Non-Executive Chairman
David Hale
President/Chief Executive Officer/Director
Michael Nall
Chief Financial Officer/Senior Vice President/Secretary
Timothy Kennedy
Senior Vice President/Chief Scientific Officer
Lyle Arnold
Senior Vice President
Cory Dunn
Senior Vice President
Michael Terry
Vice President/Director of Sales
Scott Nicholson
Other
Michael Dugan
Director
Samuel Riccitelli
Independent Director
Marsha Chandler
Independent Director
Bruce Gerhardt
Independent Director
Ivor Royston
Independent Director
Margaret Faye Wilson
  • Dividends
  • Splits
  • Insider Activity
No Data
About BIOC
Biocept, Inc. is a molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Webull offers kinds of Biocept Inc stock information, including NASDAQ:BIOC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIOC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIOC stock methods without spending real money on the virtual paper trading platform.